Marshall Wace
ACRS icon

Marshall Wace’s Aclaris Therapeutics ACRS Stock Holding History

Marshall Wace’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67M Buy
712,984
+227,483
+47% +$768K ﹤0.01% 1624
2025
Q4 		$1.46M Sell
485,501
-1,232,629
-72% -$3.11M ﹤0.01% 1745
2025
Q3 		$3.26M Sell
1,718,130
-574,319
-25% -$1M ﹤0.01% 1385
2025
Q2 		$3.26M Sell
2,292,449
-20,477
-0.9% -$27.7K ﹤0.01% 1335
2025
Q1 		$3.54M Sell
2,312,926
-321,139
-12% -$685K ﹤0.01% 1211
2024
Q4 		$6.53M Buy
+2,634,065
New +$6.55M 0.01% 951
2023
Q3 		– Sell
-30,423
Closed -$315K – 2135
2023
Q2 		$315K Buy
+30,423
New +$275K ﹤0.01% 2125
2021
Q4 		– Sell
-13,619
Closed -$245K – 3812
2021
Q3 		$245K Buy
+13,619
New +$218K ﹤0.01% 2723
2021
Q2 		– Sell
-36,612
Closed -$923K – 2600
2021
Q1 		$923K Buy
+36,612
New +$716K ﹤0.01% 1697
2019
Q2 		– Sell
-17,245
Closed -$103K – 1300
2019
Q1 		$103K Buy
+17,245
New +$114K ﹤0.01% 1431
2017
Q1 		– Sell
-466,734
Closed -$12.7M – 298
2016
Q4 		$12.7M Buy
466,734
+345,934
+286% +$8.82M 0.08% 278
2016
Q3 		$3.09M Buy
+120,800
New +$2.56M 0.02% 509

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Marshall Wace's ACRS Position: Q1 2026 in Review

Marshall Wace increased its Aclaris Therapeutics (ACRS) stake by 47% in Q1 2026, buying an estimated $768K and bringing the position to 712,984 shares worth $2.67M. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

Marshall Wace first reported a position in ACRS in Q3 2016 and has held it in 12 quarters since. The position peaked at $12.7M in Q4 2016. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Marshall Wace held 712,984 shares of Aclaris Therapeutics worth $2.67M as of Q1 2026.
  • Marshall Wace bought 227,483 Aclaris Therapeutics shares in Q1 2026, an estimated $768K.
  • Aclaris Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1624 holding.
  • Marshall Wace first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 12 quarters since.
  • Marshall Wace's Aclaris Therapeutics position peaked at $12.7M in Q4 2016.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.